Mesoblast (MESO) Income towards Parent Company (2015 - 2023)
Mesoblast (MESO) reported Income towards Parent Company of -$142.2 million for Q2 2023, up 11.57% on a YoY basis from -$127.5 million in Q2 2022, and down 862.86% sequentially from $18.6 million in Q1 2023.
Mesoblast (MESO) Income towards Parent Company (2015 - 2023) Analysis & Trends
Mesoblast (MESO) has 9 years of Income towards Parent Company data on file, last reported at -$142.2 million in Q2 2023.
- For the quarter ending Q2 2023, Income towards Parent Company rose 11.57% year-over-year to -$142.2 million; the trailing twelve-month figure through Dec 2024 stood at -$142.2 million (down 43.62% YoY), and the FY2025 full-year result was -$102.1 million, down 16.13% from the prior year.
- Income towards Parent Company declined to -$142.2 million in Q2 2023, from $18.6 million in the prior quarter.
- In the past five years, Income towards Parent Company ranged from a high of $24.6 million in Q4 2022 to a low of -$160.9 million in Q2 2022.
- A 5-year average of -$26.7 million and a median of -$23.6 million in 2020 frame the typical range for Income towards Parent Company.
- Peak annual rise in Income towards Parent Company reached 194.65% in 2022, while the deepest fall reached 629.19% in 2022.
- Tracing MESO's Income towards Parent Company over 5 years: stood at -$24.6 million in 2019, then slipped by 4.51% to -$25.7 million in 2020, then retreated by 0.98% to -$25.9 million in 2021, then soared by 194.65% to $24.6 million in 2022, then slumped by 679.24% to -$142.2 million in 2023.
- Business Quant data shows MESO's Income towards Parent Company at -$142.2 million in Q2 2023, $18.6 million in Q1 2023, and $24.6 million in Q4 2022.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - |
| 10 | Mesoblast | 19.81 Bn | 19.68 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | -142.24 Mn |
| Mar 31, 2023 | 18.65 Mn |
| Dec 31, 2022 | 24.56 Mn |
| Sep 30, 2022 | 16.94 Mn |
| Jun 30, 2022 | -160.86 Mn |
| Mar 31, 2022 | 21.29 Mn |
| Dec 31, 2021 | -25.95 Mn |
| Sep 30, 2021 | -22.65 Mn |
| Jun 30, 2021 | -22.06 Mn |
| Mar 31, 2021 | -26.52 Mn |
| Dec 31, 2020 | -25.69 Mn |
| Sep 30, 2020 | -24.54 Mn |
| Jun 30, 2020 | -32.61 Mn |
| Mar 31, 2020 | -15.26 Mn |
| Dec 31, 2019 | -24.58 Mn |
| Sep 30, 2019 | 7.42 Mn |
| Jun 30, 2019 | -20.73 Mn |
| Mar 31, 2019 | -24.97 Mn |
| Dec 31, 2018 | -38.31 Mn |
| Sep 30, 2018 | -19.50 Mn |